This finding suggests that EZH2 can be selectively targeted for RB treatment without significant effects on normal retinal cells, and also supports a rationale that lack of EZH2 expression in normal retina may confer selectivity for EZH2 targeting in RB patients. Here, EZH2 is linked to retinoblastoma.